Comparative Pharmacology
Head-to-head clinical analysis: FOSAPREPITANT DIMEGLUMINE versus PROMETHAZINE HYDROCHLORIDE PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSAPREPITANT DIMEGLUMINE versus PROMETHAZINE HYDROCHLORIDE PLAIN.
FOSAPREPITANT DIMEGLUMINE vs PROMETHAZINE HYDROCHLORIDE PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosaprepitant dimeglumine is a prodrug of aprepitant, a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. It inhibits emesis by blocking NK1 receptors in the central nervous system, particularly in the area postrema and the nucleus tractus solitarius.
Promethazine is a phenothiazine derivative that acts as a competitive antagonist at histamine H1 receptors, thereby blocking the effects of histamine. It also has anticholinergic, antiemetic, and sedative properties. In the CNS, it inhibits the chemoreceptor trigger zone and vestibular apparatus, contributing to its antiemetic effect.
150 mg intravenous over 30 minutes on day 1, combined with dexamethasone and a 5-HT3 antagonist; alternatively, 115 mg IV on day 1 followed by 80 mg IV on day 2 and 80 mg IV on day 3, or 150 mg oral (as fosaprepitant dimeglumine or aprepitant) on day 1 and 80 mg oral on days 2 and 3.
Adults: 25 mg orally or intramuscularly every 4 to 6 hours as needed; for motion sickness, 25 mg taken 30-60 minutes before departure, then every 12 hours as needed.
None Documented
None Documented
Terminal elimination half-life of aprepitant is approximately 9 to 13 hours; clinical significance includes once-daily dosing for prevention of chemotherapy-induced nausea and vomiting.
Terminal elimination half-life is approximately 10-19 hours in adults (mean ~16 hours). In children, half-life is shorter (~7-14 hours). Clinical context: Once-daily dosing may be insufficient for continuous sedation; requires every 6-8 hour dosing for sustained effect.
Fosaprepitant is rapidly converted to aprepitant. Aprepitant is eliminated primarily by metabolism; <5% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 58% of the dose, and urinary excretion accounts for 43% (mostly as metabolites).
Primarily hepatic metabolism; renal excretion of metabolites accounts for ~70% of elimination, with 20-30% as unchanged drug in urine. Fecal excretion is minimal (~5%).
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic